Last reviewed · How we verify
Allogeneic bone marrow transplantation — Treatment Landscape & Competitive Intelligence
4 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Busulfex | busulfan | Waylis | Alkylating Drug [EPC] | Matrix metalloproteinase-9 | 1954-01-01 | |
| busulfex | busulfex | Dana-Farber Cancer Institute | Matrix metalloproteinase-9 | |||
| Busilvex | Busilvex | medac GmbH | Matrix metalloproteinase-9 | |||
| Busulphan | Busulphan | University of Birmingham | Matrix metalloproteinase-9 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Dana-Farber Cancer Institute · 1 drug in Allogeneic bone marrow transplantation
- University of Birmingham · 1 drug in Allogeneic bone marrow transplantation
- Waylis · 1 drug in Allogeneic bone marrow transplantation
- medac GmbH · 1 drug in Allogeneic bone marrow transplantation
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Allogeneic bone marrow transplantation:
- Allogeneic bone marrow transplantation treatment updates — RSS
- Allogeneic bone marrow transplantation treatment updates — Atom
- Allogeneic bone marrow transplantation treatment updates — JSON
Cite this brief
Drug Landscape (2026). Allogeneic bone marrow transplantation — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/allogeneic-bone-marrow-transplantation. Accessed 2026-06-10.
Related
- Allogeneic bone marrow transplantation full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing